Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy: Opportunities for T-Cell Directed Immunotherapy
Status: Recruiting
Location: See all (3) locations...
Intervention Type: Procedure, Other
Study Type: Observational
SUMMARY
This study investigates the immune profile of patients receiving treatment with venetoclax plus azacitidine for acute myeloid leukemia (AML). Studying the information gathered from the immune profile from blood and bone marrow samples may help researchers understand the associated responses to the treatment of patients undergoing therapy of venetoclax plus azacitidine and create future immune based treatment approaches.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Adults \> 18 yrs of age with diagnosis of acute myeloid leukemia who received azacitidine plus venetoclax chemotherapy
• Treatment naive adult acute myeloid leukemia patients
Locations
United States
Arizona
Mayo Clinic in Arizona
NOT_YET_RECRUITING
Scottsdale
Florida
Mayo Clinic in Florida
RECRUITING
Jacksonville
Minnesota
Mayo Clinic in Rochester
NOT_YET_RECRUITING
Rochester
Time Frame
Start Date: 2021-04-22
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 80
Treatments
Observational (blood collection, bone marrow aspirate)
Patients undergo blood sample collection and bone marrow aspirate on study. Patients' medical records are reviewed.
Related Therapeutic Areas
Sponsors
Leads: Mayo Clinic